| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/27/2022 | 2.39% | Stifel | $11 → $18 | Maintains | Hold |
| 09/12/2022 | 42.21% | SVB Leerink | $21 → $25 | Maintains | Outperform |
| 09/12/2022 | 42.21% | HC Wainwright & Co. | $20 → $25 | Maintains | Buy |
| 08/29/2022 | 42.21% | Cowen & Co. | → $25 | Initiates Coverage On | → Outperform |
| 08/05/2022 | 19.45% | SVB Leerink | $15 → $21 | Maintains | Outperform |
| 08/05/2022 | 13.77% | HC Wainwright & Co. | $15 → $20 | Maintains | Buy |
| 08/05/2022 | 30.83% | JMP Securities | → $23 | Upgrades | Market Perform → Market Outperform |
| 02/28/2022 | -65.87% | Barclays | $11 → $6 | Downgrades | Equal-Weight → Underweight |
| 12/01/2021 | -14.68% | HC Wainwright & Co. | $25 → $15 | Maintains | Buy |
| 11/08/2021 | -43.12% | Truist Securities | $65 → $10 | Downgrades | Buy → Hold |
| 11/08/2021 | -31.74% | Canaccord Genuity | → $12 | Downgrades | Buy → Hold |
| 11/08/2021 | 42.21% | HC Wainwright & Co. | $70 → $25 | Maintains | Buy |
| 11/08/2021 | -37.43% | Barclays | $50 → $11 | Downgrades | Overweight → Equal-Weight |
| 11/08/2021 | — | Stifel | Downgrades | Buy → Hold | |
| 11/05/2021 | -43.12% | Truist Securities | $65 → $10 | Downgrades | Buy → Hold |
| 11/05/2021 | 264.05% | JMP Securities | $70 → $64 | Maintains | Market Outperform |
| 08/04/2021 | 298.18% | HC Wainwright & Co. | $75 → $70 | Maintains | Buy |
| 05/05/2021 | 326.62% | HC Wainwright & Co. | $80 → $75 | Maintains | Buy |
| 03/31/2021 | 343.69% | Credit Suisse | → $78 | Initiates Coverage On | → Outperform |
| 02/10/2021 | 298.18% | Barclays | $85 → $70 | Maintains | Overweight |
| 02/10/2021 | 298.18% | SVB Leerink | → $70 | Upgrades | Market Perform → Outperform |
| 12/03/2020 | 326.62% | Stifel | → $75 | Initiates Coverage On | → Buy |
| 11/12/2020 | 298.18% | SVB Leerink | $58 → $70 | Maintains | Market Perform |
| 09/14/2020 | 229.92% | SVB Leerink | $54 → $58 | Maintains | Market Perform |
| 08/05/2020 | 207.17% | SVB Leerink | $55 → $54 | Maintains | Market Perform |
| 05/18/2020 | 417.63% | SunTrust Robinson Humphrey | $82 → $91 | Maintains | Buy |
| 05/07/2020 | 241.3% | Nomura | $84 → $60 | Downgrades | Buy → Neutral |
| 05/07/2020 | 241.3% | Nomura | $84 → $60 | Downgrades | Buy → Neutral |
| 05/06/2020 | 178.73% | JP Morgan | $50 → $49 | Maintains | Overweight |
| 05/06/2020 | 355.06% | HC Wainwright & Co. | $60 → $80 | Reiterates | → Buy |
| 04/29/2020 | 366.44% | SunTrust Robinson Humphrey | $77 → $82 | Maintains | Buy |
| 04/29/2020 | 212.86% | SVB Leerink | $50 → $55 | Maintains | Market Perform |
| 03/04/2020 | 298.18% | Barclays | → $70 | Initiates Coverage On | → Overweight |
| 01/22/2020 | 377.82% | Nomura | $57 → $84 | Maintains | Buy |
| 01/13/2020 | 338% | SunTrust Robinson Humphrey | → $77 | Initiates Coverage On | → Buy |
| 11/05/2019 | 207.17% | JMP Securities | $45 → $54 | Maintains | Market Outperform |
| 10/29/2019 | — | SVB Leerink | Upgrades | Underperform → Market Perform | |
| 10/03/2019 | 241.3% | HC Wainwright & Co. | → $60 | Initiates Coverage On | → Buy |
| 09/30/2019 | 167.35% | Jefferies | → $47 | Initiates Coverage On | → Buy |
| 08/14/2019 | 212.86% | Cantor Fitzgerald | $43 → $55 | Maintains | Overweight |
| 08/14/2019 | 269.74% | Canaccord Genuity | $50 → $65 | Reiterates | → Buy |
| 07/18/2019 | 138.91% | Deutsche Bank | → $42 | Initiates Coverage On | → Buy |
| 03/15/2019 | 184.41% | Canaccord Genuity | $55 → $50 | Maintains | Buy |
| 09/25/2018 | 59.27% | Leerink Swann | → $28 | Initiates Coverage On | → Underperform |
| 08/29/2018 | 167.35% | Raymond James | → $47 | Initiates Coverage On | → Outperform |
| 08/23/2018 | 201.48% | Cantor Fitzgerald | → $53 | Initiates Coverage On | → Overweight |
| 08/07/2018 | 212.86% | Canaccord Genuity | → $55 | Initiates Coverage On | → Buy |
| 06/19/2018 | — | B. Riley Securities | Downgrades | Buy → Neutral | |
| 06/04/2018 | 87.71% | JP Morgan | $30 → $33 | Maintains | Overweight |
| 05/09/2018 | 144.6% | B. Riley Securities | $52 → $43 | Maintains | Buy |
| 02/16/2018 | 144.6% | B. Riley Securities | → $43 | Initiates Coverage On | → Buy |
| 10/23/2017 | 224.23% | Nomura Instinet | → $57 | Initiates Coverage On | → Buy |
| 10/23/2017 | 116.15% | JMP Securities | → $38 | Initiates Coverage On | → Market Outperform |
| 10/23/2017 | 70.65% | JP Morgan | → $30 | Initiates Coverage On | → Overweight |
Deciphera Pharmaceuticals Questions & Answers
The latest price target for Deciphera Pharmaceuticals (NASDAQ: DCPH) was reported by Stifel on September 27, 2022. The analyst firm set a price target for $18.00 expecting DCPH to rise to within 12 months (a possible 2.39% upside). 16 analyst firms have reported ratings in the last year.
The latest analyst rating for Deciphera Pharmaceuticals (NASDAQ: DCPH) was provided by Stifel, and Deciphera Pharmaceuticals maintained their hold rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Deciphera Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Deciphera Pharmaceuticals was filed on September 27, 2022 so you should expect the next rating to be made available sometime around September 27, 2023.
While ratings are subjective and will change, the latest Deciphera Pharmaceuticals (DCPH) rating was a maintained with a price target of $11.00 to $18.00. The current price Deciphera Pharmaceuticals (DCPH) is trading at is $17.58, which is within the analyst's predicted range.